Passage Bio

Passage Bio is a clinical-stage genetic medicines company focused on developing gene therapies for neurodegenerative and other central nervous system diseases. The company’s pipeline includes AAV-based programs aimed at treating rare monogenic CNS disorders and related neurodegenerative conditions.

Relationship details are part of the Pro plan.